# Doctors Hospital Health System Limited Interim report Quarter ended July 31, 2025

## Chairman's Report Doctors Hospital Health System Limited

Dear Shareholder,

On behalf of the Board of Directors of Doctors Hospital Health System Limited ("the Company" or "the Health System"), I report on the Company's financial results for the six months ended July 31, 2025.

Consolidated net profit for the six months was \$3,527,377 compared to \$2,738,232 for the comparable period in fiscal 2025. Consolidated net patient services revenue increased \$3,371,479 or 5.63% over the 2nd quarter last year. Kidney Centre Limited, which the Company acquired in the 2<sup>nd</sup> quarter of fiscal 2025, contributed \$4.4m in net patient services revenues, of which \$2.2m was earned in the 1<sup>st</sup> quarter. Beyond the effects on Kidney Center Limited, revenues also grew due to an increase in inpatient activity and ongoing strong demand at the Company's pre-hospital (outpatient) locations.

Total inpatient days for the six months ended July 31, 2025 were 5,579, an increase of 5.58% from the comparable period last year. Total patient visits for the six months ended July 31, 2025 were 22,608, an increase of 11.52% from the comparable period in the prior year.

The Company's outpatient clinic on Paradise Island opened in the 3<sup>rd</sup> quarter of fiscal 2025.

The Company's net revenues continue to grow based on the Health System's expansion efforts, notwithstanding that critical care revenues have yet to rebound to pre-COVID levels. In FYE 2025, the Health System commenced a planned changeout to its interventional catheterization laboratory ("Cath Lab"), materially impacting inpatient admissions and revenue in the ICU and IMCU. Management anticipates an expanded revenue structure once the new Cath Lab is online, indicatively in the 1<sup>st</sup> quarter of fiscal 2027.

Consolidated expenses increased by \$2,541,567 or 4.36% over the comparable period last year. Notable increases in consolidated expenses were incurred in the following:

- Salaries & benefits (\$1.97 million or 7.3%) due to increased benefit costs (primarily group medical insurance) combined with the increased salaries costs driven by the acquisition of Kidney Centre Limited ("KCL"). Over the comparable period last year, KCL was acquired during the second quarter so there was no consolidation for 3 months of the prior year.
- Medical services (\$696 thousand or 11.7%) This expense for contracted physicians is directly related to the change in revenue.
- Contracted Services (\$979 thousand or 61.2%) During the current year, the Company entered into additional service contracts, some of which are one-time and tied to ongoing expansionary efforts.

Demonstrating increased cost control not tied to expansion specifically, the Company notes there have been declines in other variable expenses, primarily the following:

• Impairment loss (\$1.82 million or 73.7%) – This decline in the current year is primarily due to changes in accounts receivable balances and forward-looking estimates, resulting in an overall reduction in the impairment loss. The rate of uncompensated care remains a material risk for the Health System, impacting financial performance for both self-pay customers and partial payments or denials from thirty party payors.

The Company continues to exercise expense control and tighten spending in discretionary areas. Focus areas include those which drive/support the business – procurement of quality medical supplies at lower costs, monitoring of and reduction in wastage/excesses throughout the Health System and sustainability efforts with respect to utilities, which will drive down costs in the longer term.

The Company's return on sales (net income margin) increased to 5.48% for the six months ended July 31, 2025, an increase of 22.05% compared to the same period last year of 4.49%. This performance reflects efficiency improvements year over year. It is a result of revenue growth combined with overall expense management.

The Board and Management team wish to thank you, our valued shareholders, Physicians, and all Associates for your continued support and loyalty to the Health System.

We look forward to continuing to provide an excellent customer experience to our patients and visitors, whose loyalty we also appreciate and value.

Felix Stubbs Chairman September 17, 2025

Consolidated Statement of Financial Position

July 31, 2025 with comparative figures at January 31, 2025 (Expressed in thousands of Bahamian dollars)

		ıly 31, 2025	January 31, 2025
Assets			
Current assets:			
Cash and cash equivalents	\$	4,972	8,711
Trade receivables, net (note 2)		46,503	40,031
Inventories		5,387	5,073
Other assets		3,419	1,874
		60,281	55,689
Non-current assets:			
Other assets		687	687
Investments		7,121	7,315
Investment property		874	901
Goodwill, net		3,406	3,406
Other intangible assets		3	3
Right of use assets		3,279	4,241
Property, plant and equipment		83,859	81,546
		99,229	98,099
Total assets	\$	159,510	153,788
Liabilities and Shareholders' Equity Current liabilities: Accounts payable and other liabilities Provisions Lease liabilities, current portion Long-term debt, current portion  Long-term liabilities: Lease liabilities Long-term debt	\$	31,986 80 1,804 361 34,231 1,668 18,139 19,807	30,580 80 1,889 357 32,906 2,570 16,367 18,937
Total liabilities		54,038	51,843
Shareholders' equity: Share capital: Authorized 18,750,000 common shares at par value of B\$0.04 each (January 31, 2025 – 18,750,000 shares) Issued and fully paid 12,471,634 shares (January 31, 2025 – 12,471,634 shares) Share premium		499 30,748	499 30,748
Retained earnings		74,225	70,698
		105,472	101,945
Total liabilities and shareholders' equity	\$	159,510	153,788

Consolidated Statement of Comprehensive Income

Three months ended July 31, 2025 with comparative figures for the three months ended July 31, 2024 (Expressed in thousands of Bahamian dollars)

		ly 31, 2025	July 31, 2024	
Revenues				
Patient service revenue, net	\$	31,340	30,758	
Other		493	535	
Total revenues		31,833	31,293	
Expenses				
Salaries and benefits		14,737	13,505	
Medical supplies		4,087	3,666	
Medical services		3,564	3,166	
Impairment loss		(858)	2,016	
Depreciation and amortization		1,809	1,784	
Other operating		2,311	2,441	
Utilities		979	874	
Government taxes and fees		428	447	
Contracted services		1,171	808	
Insurance		758	710	
Repairs and maintenance		708	431	
Rent		(55)	(55)	
Dietary expenses		<b>170</b>	125	
Legal expenses		10	196	
Interest expense		79	144	
Total expenses		29,898	30,258	
Net income & total comprehensive				
income for the period	\$	1,935	1,035	
Earnings nor common share (expressed in Bohamian dellars)				
Earnings per common share (expressed in Bahamian dollars): Basic and fully diluted	\$ <b>\$</b>	0.16	0.09	

Consolidated Statement of Comprehensive Income

Six months ended July 31, 2025 with comparative figures for the six months ended July 31, 2024 (Expressed in thousands of Bahamian dollars)

	July 31, 2025		July 31, 2024	
Revenues				
Patient service revenue, net	\$	63,269	59,897	
Interest income		181	167	
Other		878	933	
Total revenues		64,328	60,997	
Expenses				
Salaries and benefits		28,948	26,979	
Medical supplies		7,624	7,676	
Medical services		6,672	5,957	
Impairment loss		648	2,465	
Depreciation and amortization		3,247	3,176	
Other operating		4,479	4,444	
Utilities		1,880	1,499	
Government taxes and fees		1,053	1,098	
Contracted services		2,578	1,599	
Insurance		1,573	1,240	
Repairs and maintenance		1,355	1,177	
Rent		115	(20)	
Dietary expenses		339	308	
Legal expenses		150	399	
Interest expense		140	262	
Total expenses		60,801	58,259	
Net income & total comprehensive				
income for the period	\$	3,527	2,738	
Return on sales (net income margin)		5.5%	4.5%	
Earnings per common share (expressed in Bahamian dollars):				
Basic and fully diluted	Φ	0.28	0.23	
Dasic and fully unded	\$	U.20	0.23	

Consolidated Statement of Changes in Equity

Six months ended July 31, 2025 (Expressed in thousands of Bahamian dollars)

	Number of shares	Share capital	Share premium	Retained earnings	Total
Balance at January 31, 2025	12,471,634	\$ 499	\$ 30,748	\$ 70,698	\$ 101,945
Net income for the period	_	-	_	3,527	3,527
Balance at July 31, 2025	12,471,634	\$ 499	\$ 30,748	\$ 74,225	\$ 105,472

Consolidated Statement of Cash Flows

Six months ended July 31, 2025 with comparative figures for the six months ended July 31, 2024 (Expressed in thousands of Bahamian dollars)

	July 31, 2025	July 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income	\$ 3,527	2,738
Adjustments to reconcile net income to net cash	Ψ 0,821	2,730
provided by operating activities:		
Depreciation and amortization	3,247	3,176
Impairment loss	648	2,465
Interest income	(181)	(167)
Interest expense	140	262
Operating income before working capital changes	7,381	8,474
Increase in accounts receivable	(7,120)	(1,524)
(Increase)/decrease in inventories	(314)	75
(Increase)/decrease in other assets	1,520	791
Increase in accounts payable and other liabilities	1,406	7,645
Cash (used in)/generated from operating activities	2,873	15,461
Interest paid	(349)	(262)
Net cash (used in)/from operating activities	2,524	15,199
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of property, plant and equipment, net	(4,571)	(16,171)
Purchase of investments	(249)	_
Proceeds from maturity of investments	55	274
Interest received	81	82
Net cash used in investing activities	(4,684)	(15,815)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Repayment of long-term debt	(1,525)	(191)
Proceeds from issuance of long-term debt	956	6,975
Payment of lease liabilities	(1,010)	(823)
Net cash used in financing activities	(1,579)	6,007
Increase/(decrease) in cash and cash equivalents	(3,739)	5,391
Cash and cash equivalents at beginning of period	8,711	1,981
Cash and cash equivalents at end of period	\$ 4,972	7,372

Cash and cash equivalents comprise cash at bank and in hand, and short-term deposits with an original maturity of three months or less.

Notes to Interim Consolidated Financial Statements

Six months ended July 31, 2025

## 1. Significant accounting policies

These interim financial statements have been prepared in accordance with International Accounting Standard No. 34, Interim Financial Reporting; using the same accounting policies applied in the January 31, 2025 audited consolidated financial statements.

#### 2. Accounts receivable

Accounts receivable are stated net of provisions for doubtful accounts of \$19.0 million.